West Pharmaceutical Services (WST) Q3 2025 Earnings
How Did WST Stock React to Q3 2025 Earnings?
S&P 500 over the same 30 days: −0.45%.
Did WST Beat Earnings? Q3 2025 Results
Yes. West Pharmaceutical Services reported Q3 2025 earnings of $1.96 a share on Oct 23, 2025, beating the $1.69 consensus estimate by 16.3%. Revenue was $804.6M against a $787.7M estimate.
West Pharmaceutical Services posted a standout third quarter, with adjusted diluted EPS of $1.96 beating the $1.69 consensus estimate by 15.98% as surging demand for GLP-1 drug delivery components lifted results well above expectations. Net sales climbed 7.7% year-over-year to $804.60 million, anchored by a 16.3% jump in High-Value Product Components to $390.00 million, driven by elastomers tied to obesity and diabetes therapies and Annex 1 regulatory conversion activity. GLP-1-related products accounted for a combined 17% of total company revenues in the quarter, underscoring how meaningfully that end market has reshaped West's revenue mix. Gross margin expanded 120 basis points to 36.6%, reflecting the favorable shift toward higher-margin HVP products. Management responded to the momentum by raising full-year 2025 net sales guidance to $3.06 billion–$3.07 billion and meaningfully lifting adjusted EPS guidance to $7.06–$7.11, from a prior range of $6.65–$6.85. The results drew fresh analyst attention, with at least one coverage initiation citing West's positioning in injectable biologics and GLP-1 as a basis for sustained revenue and margin expansion ahead.
- Double-digit growth in HVP Components driven by GLP-1 products, Annex 1 conversions, and improving demand environment
- GLP-1 elastomers represented 9% of total company revenues in Q3
- GLP-1 Contract Manufacturing revenues represented 8% of total company revenues in Q3
- Biologics market group accounted for 41% of revenue, growing 11.0% YoY
- Annex 1 regulatory conversions tracking ahead of expectations, driving approximately 200 bps of FY25 sales growth
- Gross margin expanded 120 bps to 36.6% driven by favorable product mix shift to HVP
- Contract Manufacturing growth driven by self-injection devices for obesity and diabetes
“I am pleased to report that we delivered another solid quarter, with both revenues and profits exceeding our guidance. Our strength was broad-based, across both our Proprietary Products and Contract Manufacturing segments. We achieved double-digit growth in our HVP Components business, driven by our continued execution in GLP-1 products, increased HVP conversion, including Annex 1, and an overall improving demand environment. As a result of the solid performance in the quarter, and the ongoing momentum in our business, we are again increasing our full-year guidance expectations.”
West Pharmaceutical Services CEO, on the earnings call
What Was West Pharmaceutical Services's Outlook in Q3 2025?
West raised its full-year 2025 net sales guidance to $3.060 billion–$3.070 billion (from $3.040 billion–$3.060 billion), implying reported growth of 5.8%–6.1% and organic growth of 3.75%–4.0%. Full-year adjusted-diluted EPS guidance was increased to $7.06–$7.11 (from $6.65–$6.85), representing 4.6%–5.3% growth over 2024 actual adjusted EPS of $6.75. Fourth-quarter 2025 guidance calls for net sales of $790 million–$800 million (organic growth of 1.0%–2.3%) and adjusted-diluted EPS of $1.81–$1.86. Capital spending guidance is unchanged at $275 million. Full-year guidance includes an estimated $59 million benefit from foreign currency exchange rates and $0.27 EPS benefit from FX. The company expects Annex 1 regulatory conversions to drive approximately 200 basis points of FY25 sales growth.
WST YoY Financials
| Metric | Q3 2025 | Q3 2024 | Year over year |
|---|---|---|---|
| Revenue | $804.6M | $746.9M | +7.7% |
| Gross Profit | $294.3M | $265.2M | +11.0% |
| Operating Income | $167.6M | $167.8M | −0.1% |
| Net Income | $140.0M | $136.0M | +2.9% |
WST Revenue by Segment
WST Revenue by Geography
Figures from SEC filings and company reports. Not investment advice.